RVTYNYSELaboratory Analytical InstrumentsFiscal year ends December 29
REVVITY, INC.
Financials through Q2 FY2026, quarter ended Jul 5, 2026Last filing: 10-Q on Aug 11, 2026
$150.94−1.70 (-1.11%)
Close on Oct 19, 2026
- Market cap
- $16.85B
- P/E (TTM)
- 71.9
- Dividend yield
- 0.19%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
12.5%−20.1 pts over 5 years
Net margin
8.4%−18.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +3.7% | -4.8% | +1.4% | +3.1% | |
| Operating income | +2.9% | -21.7% | -16.3% | +3.6% | |
| Net income | -10.8% | -24.9% | -19.8% | +1.3% | |
| EPS, diluted | -5.9% | -22.8% | -20.4% | +1.0% | |
| Free cash flow | -6.0% | -5.0% | -9.3% | +7.0% | |
| Dividend per share | 0.0% | 0.0% | 0.0% | 0.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 11.0% | 22.2% | 3.2% | |
| Return on assets | 5.6% | 10.0% | 2.0% | |
| Current ratio | 1.97 | 1.36 | 1.68 | |
| Debt to equity | 0.49 | 0.53 | 0.44 | |
| Net debt to EBITDA | 1.70× | 1.49× | 3.02× | |
| Interest coverage | 7.1× | 17.4× | 3.9× | |
| Inventory turnover | 4.4× | 1.3× | – | |
| Capex to revenue | 1.5% | 2.4% | 2.6% | |
| Diluted shares | 110M | 112M | 117M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Revvity generated $3.39B from operations and spent $2.32B on capital expenditure, dividends and share buybacks. 18% of that went back into the business.
Generated
$3.39B
Used
$2.32B
Capital expenditure$413.19M18%Dividends$169.94M7%Share buybacks$1.73B75%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin8.4%
×Asset turnover0.23×
×Equity multiplier1.65×
=Return on equity, FY20253.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 8.4% | 0.23× | 1.65× | 3.2% |
| FY2024 | 9.8% | 0.21× | 1.67× | 3.5% |
| FY2023 | 25.2% | 0.20× | 1.82× | 9.1% |
| FY2022 | 17.2% | 0.23× | 2.01× | 7.8% |
| FY2021 | 24.6% | 0.33× | 2.11× | 17.3% |
| FY2020 | 27.3% | 0.37× | 2.21× | 22.2% |
| FY2019 | 7.9% | 0.46× | 2.32× | 8.4% |
| FY2018 | 8.6% | 0.46× | 2.37× | 9.4% |
| FY2017 | 13.0% | 0.44× | 2.23× | 12.6% |
| FY2016 | 11.1% | 0.50× | 1.98× | 11.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$241.20M
- Cash generatingOperating cash flow above zero$582.93M
- Return on assets improvedROA up on the prior year2.0% → 1.9%
- Earnings backed by cashOperating cash flow above net income$582.93M vs $241.20M
- Less leverageLong-term debt to assets fell25.4% → 21.6%
- Better liquidityCurrent ratio rose3.60 → 1.68
- No dilutionShare count did not rise123M → 117M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.20 → 0.23